{"ticker": {"uuid": "bf18b3a4-eeef-4a4b-b84d-0afe6a3b4d6c", "symbol": "IPHA", "name": "Innate Pharma", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Innate Pharma (IPHA) Edges Higher Near Key Support; Resistance at $1.88 in Focus - Breakaway Gap", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNSDQ5N0MzYUhoLUVzeE9pYWZmQmRlTlNLU2t5N2dPZ1RkY3ZSbU9UaEJQVDc2WE1DX2dnbzNXVi0tdEphS1Q3ME5nSnh3TERHR0ZHZ09USUxxamh4dlFOTjBVQzhCSDlpbm93alJnSW43emNzQ05IZ1cxc3VreEp5eXlfWGQ5QVBaWnFwaHlBdl9paHJpS3E2ZTJQOFNveE5ZM2dqOXFaX2JZaTYxSFRJUjllQno0T1d3bWZBMw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-13T00:30:04+00:00", "published_display": "13 Jul 2026 00:30", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (IPHA) Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical Investment Intensifies - Growth Acceleration Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPLTU4LVFBYnBMOVNNXzFuN05QNkhSX1p3b1FiQUp2V2RCLW1HNUdRUDdqTUtHb2VPcTlPWmtIcUR0TXhpTnJVVEY3OFFsQ29MV1hteFlNQU5ENXpsd195QzFudHlTeF9qRnk4VTBMU0JIZ25iLUZYNWgzTXFkVWNNcVN4dFh4WDJlT0tac1VPWWQxM1daZFZ5TlRINTI0LW9Bb1BQYm9EYkdrSEFrd043cER1enZuSk1WZE9rVTNiTlV0OEdja09DNlIwcG1tR3FzODJpaFFReEVJZEk?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-06T19:48:08+00:00", "published_display": "06 Jul 2026 19:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (IPHA) Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical Investment Intensifies - Guidance Revision Trend", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxQaVNIc1lzSWllRlpHeWQ4aDd3Tm5EN3JxOGE4NGFWcDNtT1l0TlhyWnJndk13ZmdiTjZlUmR0cC10ZDMyNktHb0plN1JHUGNGSVd1azhJWUtodmt3V2pqQjNyWExpX1RQUDZ4R3dnaGdVN3NhN2wwQjVHZXdwSG9qVy1hWTduSEhqcEwtT1FCQk82TnBEVFdPQnpzMG5BY294cWpWeEdsYWIyZVZfRThSMnJuSWFVdXpaZ2dhTFRYYlctRFlrNTZoalNRdVZtZnNrbVZ4OEhCekI?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-06T19:40:24+00:00", "published_display": "06 Jul 2026 19:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma(IPHA) Stock Options Chain | Quotes & News", "summary": "This article provides the stock options chain, quotes, and news for Innate Pharma (IPHA). It serves as a resource for investors interested in the company's financial performance and market derivatives. The content helps users access relevant financial data and recent updates for ", "url": "https://www.moomoo.com/stock/IPHA-US/options-chain?chain_id=Name1K9-3FXPhg.1kvnlg0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fstock%2F300300-SZ%22%7D", "source_name": "Moomoo", "published_at": "2026-07-06T20:10:53", "published_display": "06 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 2026 Innate Pharma SA Corporate Sales Call Transcript", "summary": "This document is a transcript of Innate Pharma SA's Q1 2026 Corporate Sales Call, which took place on May 13, 2026, at 11:30 AM GMT. The call covered the company's business and financial results for the first quarter of 2026, with a question-and-answer session following the initi", "url": "https://www.gurufocus.com/stock/CHIX:IPHP/transcripts/8856229", "source_name": "GuruFocus", "published_at": "2026-07-02T14:40:34", "published_display": "02 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Innate Pharma SA Class A \u2013 EURONEXT:IPH", "summary": "This article provides the \"Price to earnings forward\" value for Innate Pharma SA Class A (EURONEXT:IPH) as presented on TradingView. The page indicates the market is closed with no trades. It also highlights the data sources and copyright information for the financial data presen", "url": "https://www.tradingview.com/symbols/EURONEXT-IPH/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T16:40:49", "published_display": "30 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Innate Pharma SA Class A \u2013 EURONEXT:IPH", "summary": "This article displays the enterprise value to EBITDA forward for Innate Pharma SA Class A (EURONEXT:IPH) on TradingView. It appears to be a financial data snippet rather than a full analytical report, showing the period, value, and change percentages for this metric. The main con", "url": "https://www.tradingview.com/symbols/EURONEXT-IPH/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T15:39:53", "published_display": "28 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Innate Pharma SA Class A \u2013 EURONEXT:IPH", "summary": "This page provides financial information for Innate Pharma SA Class A (EURONEXT:IPH), specifically focusing on its Price to Sales Forward metric. The content highlights that the market was closed with no trades at the time of viewing, indicating a static financial snapshot for th", "url": "https://www.tradingview.com/symbols/EURONEXT-IPH/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:10:33", "published_display": "26 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Innate Pharma SA Class A \u2013 EURONEXT:IPH", "summary": "The page displays information regarding the \"Price to book forward\" for Innate Pharma SA Class A (EURONEXT:IPH). The article is primarily a data placeholder from TradingView, indicating financial metrics for the company.", "url": "https://www.tradingview.com/symbols/EURONEXT-IPH/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:11:43", "published_display": "25 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amendment: Innate Pharma (NASDAQ: IPHA) shows Novo Nordisk 0% ownership", "summary": "Novo Nordisk A/S filed an amended Schedule 13G/A, reporting zero beneficial ownership of Innate Pharma's ordinary shares, representing 0.00% of the company. The filing, signed by CFO Karsten Munk Knudsen on June 22, 2026, is an administrative amendment indicating no current discl", "url": "https://www.stocktitan.net/sec-filings/IPHA/schedule-13g-a-innate-pharma-sa-amended-passive-investment-disclosure-b870c4209af9.html", "source_name": "Stock Titan", "published_at": "2026-06-22T12:09:57", "published_display": "22 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13G Innate Pharma SA For: 22 June By Investing.com", "summary": "This article from Investing.com announces the filing of Form 13G for Innate Pharma SA (IPH) on June 22. It is a brief news item indicating a regulatory filing has occurred, primarily serving as an update for investors following the company. The content itself is very short and di", "url": "https://ng.investing.com/news/stock-market-news/form-13g-innate-pharma-sa-for-22-june-93CH-2567598", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T10:10:55", "published_display": "22 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma SA (IPHA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Innate Pharma SA (IPHA), focusing on its P/E, P/B, and Fair Value. The analysis indicates that relevant data for P/E, P/B, P/S, and P/CF have not yet been disclosed by the company. TradingKey provides this information as part of its ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ipha/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T16:40:10", "published_display": "18 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma SA (IPHA) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Innate Pharma SA (IPHA), detailing various metrics related to volatility, financial risk, and investment risk. It includes data on beta, VaR, maximum drawdown, daily returns, Sharpe Ratio, and turnover rates across different timeframes.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ipha/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:28", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma SA (IPHA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Innate Pharma SA (IPHA) has an average analyst rating of \"Buy\" based on 4 analysts, with a target price of USD 6.00, suggesting a significant upside. The article highlights that relevant earnings per share (EPS), revenue, net profit, and EBIT data have not yet been disclosed by t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ipha/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:27", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma SA (IPHA) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Innate Pharma SA's (IPHA) institutional confidence, including its current stock price, market capitalization, and a list of institutional shareholders. Key shareholders like AstraZeneca PLC and Lion Point Capital, L.P. are list", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ipha/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:27", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma SA (IPHA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Innate Pharma SA's (IPHA) dividend and stock split history. It states that the company has not distributed any dividends over the past five years and contains no record of historical stock splits. The page also displays current stock quotes an", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ipha/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T18:09:54", "published_display": "17 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma SA (IPHA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey focuses on Innate Pharma SA's (IPHA) revenue breakdown, noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It provides current stock information for IPHA, includ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ipha/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T18:09:54", "published_display": "17 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IPHA - Innate Pharma ADR Stock Price and Quote", "summary": "This page provides detailed financial information, stock performance data, and news updates for Innate Pharma ADR (IPHA). It includes key metrics such as market cap, income, sales, and various financial ratios, alongside a comprehensive list of analyst ratings and historical news", "url": "https://finviz.com/stock?t=IPHA", "source_name": "Finviz", "published_at": "2026-06-06T16:12:17", "published_display": "06 Jun 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (IPHA) Q1 2026 Earnings: Deep EPS Miss Weighs on Shares as Pipeline Progress Remains in Focus - Surprise Factor Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOT1EzeEZsbk91YmVtOHlkQ3g4YTI4UEJiSG5pRmVCcHM3Wlo2RUpPMG5VbjhLMkhBWXQxZXFNZml4TjAzWHd6UE9zNEl3YVduZ2xHWkx4Y3MyeHZrUm9BMFlMS0RtYXJuQXpGWVBVM2lxQVhtbGZGc2xzYWdIdHNxZjVGUHpWaXBZb3BEc0U0a0RVeFRQVEhlT0ZPSUY1cUFKSnltX3lzbnE4Ujd0NnhXbzhkTzVSdHlGcW4xS0tFdlhBTFd5T0poSzZDNjJ2Q3pzNlNsSVZpaWsxYkJtRG1J?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (Nasdaq: IPHA) outlines 2026 AGM quorum and key pipeline focus", "summary": "Innate Pharma (Nasdaq: IPHA) announced the voting results of its 2026 Annual General Meeting held on May 21, 2026, in Marseille. All resolutions were voted upon, with a total of 94 votes cast representing 34,921,313 voting rights and achieving a 37,136% quorum. The company also h", "url": "https://www.stocktitan.net/sec-filings/IPHA/6-k-innate-pharma-sa-current-report-foreign-issuer-f698fc38e19d.html", "source_name": "Stock Titan", "published_at": "2026-05-22T09:40:13", "published_display": "22 May 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outcome of Innate Pharma\u2019s 2026 Annual General Meeting", "summary": "Innate Pharma SA announced the voting results of its 2026 Annual General Meeting held on May 21, 2026, in Marseille. All proposed resolutions were approved by shareholders, with details available on the company's website. Innate Pharma is a clinical-stage biotechnology company fo", "url": "https://www.biospace.com/press-releases/outcome-of-innate-pharmas-2026-annual-general-meeting", "source_name": "BioSpace", "published_at": "2026-05-22T09:09:39", "published_display": "22 May 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholder turnout and votes at Innate Pharma\u2019s 2026 annual meeting", "summary": "Innate Pharma SA announced the voting results of its Annual General Meeting (AGM) held on May 21, 2026, in Marseille. All resolutions were passed, with a quorum of 37,136% representing 94 votes cast out of 34,872,293 shares. The company is a clinical-stage biotechnology firm focu", "url": "https://www.stocktitan.net/news/IPHA/outcome-of-innate-pharma-s-2026-annual-general-0itg9xbxnlrv.html", "source_name": "Stock Titan", "published_at": "2026-05-22T01:00:00", "published_display": "22 May 2026 01:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma to Court Investors at Jefferies Global Healthcare Conference 2026", "summary": "Innate Pharma SA announced that its executive team will hold one-on-one investor meetings at the Jefferies Global Healthcare Conference from June 2 to 4, 2026, in New York. The company aims to showcase its oncology pipeline, including assets like Nectin-4 ADC IPH4502, to U.S. inv", "url": "https://www.tipranks.com/news/company-announcements/innate-pharma-to-court-investors-at-jefferies-global-healthcare-conference-2026", "source_name": "TipRanks", "published_at": "2026-05-19T10:39:20", "published_display": "19 May 2026 10:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (Nasdaq: IPHA) to meet investors at Jefferies Global Healthcare Conference 2026", "summary": "Innate Pharma S.A. (Nasdaq: IPHA), a clinical-stage biotechnology company, announced its executive team will attend the Jefferies Global Healthcare Conference 2026 from June 2-4 in New York for one-on-one investor meetings. The company will showcase its pipeline of antibody-based", "url": "https://www.stocktitan.net/sec-filings/IPHA/6-k-innate-pharma-sa-current-report-foreign-issuer-b11c9bbd35e1.html", "source_name": "Stock Titan", "published_at": "2026-05-19T09:39:20", "published_display": "19 May 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma to participate in the Jefferies Global Healthcare Conference", "summary": "Innate Pharma SA, a clinical-stage biotechnology company focused on cancer immunotherapies, announced that its executive team will attend the Jefferies Global Healthcare Conference in New York from June 2\u20134, 2026. The team will participate in one-on-one investor meetings at the e", "url": "https://www.businesswire.com/news/home/20260518085378/en/Innate-Pharma-to-participate-in-the-Jefferies-Global-Healthcare-Conference", "source_name": "Business Wire", "published_at": "2026-05-19T07:40:16", "published_display": "19 May 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Innate Pharma Q1 2026 beats earnings expectations By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQdzJXV3dYM2RPQ3NkOTBSRFRfTy10OENPVDVFcEplVEJHb2ZLcEhKQ2h4U1ktekFTYmRiX1pkOVZjVmMzSnFNQW1EemlSMm1mYm1DUEZucmFtRUFZUmtQQzNFUWttVC1Lb1ZmSW96RERsQm5lREplc0dlOE5hakFOOHBHMHcxdTNsdzZ4Yk5BQ0xDbHVXcTcyT1VwbzF4a3A1eE92MkxtRXNJXzd3LTN5aWltajhZcXRSc1lPem9lZWxUUXIwWlg1MjNZak41d0ZS?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma S.A. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:IPHA) 2026-05-15", "summary": "This article announces that Innate Pharma S.A. has published its slide deck in conjunction with its 2026 Q1 earnings call. The content is provided by SA Transcripts, which focuses on developing and publishing earnings call transcripts.", "url": "https://seekingalpha.com/article/4905521-innate-pharma-s-a-2026-q1-results-earnings-call-presentation", "source_name": "Seeking Alpha", "published_at": "2026-05-16T00:09:51", "published_display": "16 May 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "H.C. Wainwright Maintains Innate Pharma(IPHA.US) With Buy Rating, Maintains Target Price $5", "summary": "H.C. Wainwright has reiterated its Buy rating for Innate Pharma (IPHA.US), maintaining a target price of $5. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance and potential.", "url": "https://www.moomoo.com/news/post/70005168/hc-wainwright-maintains-innate-pharma-iphaus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-05-15T02:40:36", "published_display": "15 May 2026 02:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma S.A. (NASDAQ:IPHA) Q1 2026 Earnings Call Transcript", "summary": "Innate Pharma S.A. held its Q1 2026 earnings call, exceeding EPS expectations. The company provided updates on its key pipeline assets: lacutamab, IPH4502, and partnered programs with AstraZeneca (monalizumab and IPH5201). Important upcoming milestones include the initiation of t", "url": "https://www.insidermonkey.com/blog/innate-pharma-s-a-nasdaqipha-q1-2026-earnings-call-transcript-1762053/", "source_name": "Insider Monkey", "published_at": "2026-05-14T12:38:54", "published_display": "14 May 2026 12:38", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "IPHYF SEC Filings - Innate Pharma Marseille 10-K, 10-Q, 8-K Forms", "summary": "This article provides an overview of Innate Pharma S.A.'s (IPHYF) SEC filings, including 10-K, 10-Q, and 8-K forms, which detail the company's financial performance, oncology pipeline, and strategic collaborations. Recent filings highlight a 2025 net loss of \u20ac49.2 million with si", "url": "https://www.stocktitan.net/sec-filings/IPHYF/page-2.html", "source_name": "Stock Titan", "published_at": "2026-05-14T01:09:54", "published_display": "14 May 2026 01:09", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/f1f21d9b-235c-33d9-adbf-b83a4838b6df/innate-pharma-q1-earnings.html", "source_name": "MarketBeat", "published_at": "2026-05-13T16:07:22+00:00", "published_display": "13 May 2026 16:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (Nasdaq: IPHA) details Q1 2026 cash runway and trial plans", "summary": "Innate Pharma reported its Q1 2026 business update, highlighting plans for the TELLOMAK-3 confirmatory Phase 3 trial for lacutamab, contingent on non-dilutive financing. The company also provided updates on other pipeline assets, including IPH4502 and IPH5201, while noting its ca", "url": "https://www.stocktitan.net/sec-filings/IPHA/6-k-innate-pharma-sa-current-report-foreign-issuer-be09b6d5b541.html", "source_name": "Stock Titan", "published_at": "2026-05-13T12:09:12", "published_display": "13 May 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (IPHA) Reports Strong Revenue Growth in Q1 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQVmJwcGNEWVc4c3MyWHFqSGlhMFU1ODNqRVZKVDdIYXZveWVNbVY0dWI2dW1MRWlqalQxR2xuN2JEdjY3MEk2c1A5cldkQVdaUi13OVloNndwYWczcUlVLXdMR01GR2dzczd6ZjdmZFlwaVQ0eUx4LUNhYTdZd1h1Vm9HTGRScGtKd2F4ZXZnTjVJRXZGME5hTE00eUNZZGRsd0R0WFFjRmdXVzZ6emxn?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026", "summary": "Quantisnow published a press release detailing the number of shares and voting rights for Innate Pharma S.A. (IPHA) as of April 16, 2026. Quantisnow Plus members received an alert about this publication almost immediately after it was released. The platform provides real-time mar", "url": "https://www.quantisnow.com/insight/number-of-shares-and-voting-rights-of-innate-pharma-as-6546304", "source_name": "Quantisnow", "published_at": "2026-05-12T17:09:13", "published_display": "12 May 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Innate Pharma reports interim lung cancer trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPd2lIaDZzRHBoR2N2cW5MaE1yRzNsTVlyaWVsNDlrV2kyV2NrNVJVSTZpUjlBbHp0amZjazRRMWdhb19VVW1BU3ZUU2NNbUpTQzNWYXJJdXRWUnNoZG1SdmVBWWIycmx6YlIxbEI1MkhTRm5vT3RYU3N0T1lTZHV6OHFNWDFyRWZyLUFtUzhIam9uRGo3TDBHMjUzclRNU21yUDd0VEtQSGhSNDZvbFNQQWVR?oc=5", "source_name": "Investing.com", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma posts 2025 annual reports to French and US regulators", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNVi1Vakg5Q29XZE9kNnhLdWJaSUROeEhIWHRUcXBPUzd3Q1lmeGRKZjBoR090eUhCOUlwZnRCaE5kX0F2YzBPSjhQd3JESmd2WHN6eE5zM0QtcGtYdTF2M2Q2emZpS096MHh4bG80My01Sk0waXRKUlEtYUd1RWl3RVRubC12TEozRmt5Ql9zXzIxNWxJdTBoc1JOTm5pcFpNY1ZNMS1fSnE2S3ZVZXhJNHNIRDdpZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxNMENsbktULU5ZRFVEb1RocjI4VkZKX1Q4TzhvTHBpSklmTXpwcnlSWHhKQjhzNGpRcG5fT1ZscHJzU2xzbGg3Q015ZVoyN2lPMGVMRXI0dHdiT09FTDl2QlppZU1lNldpUVNMU1lqNHN5U2k2Rlo0cUxuOWJjTmR5WGluX2Iyb25qZnFFMVN1X0NfMWdGdTh0RFB4YmstVFpFVDlDVmVybVlZdW0yOEIwcnltSzhBdDRnS2pzVjBYNTE3eW5STzk2TlRzNzFqRTYzTFMyMWNB?oc=5", "source_name": "Investing.com", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (IPHA) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE5EV2Y3OVBiSG1IMzJtV1lMenY5bFh0ZlFXd2ZxSzlHTWJvWkk2T3VGR1JSZHVSelRDVnM3SFFRWkk3dDFfREpnY1hweW5GYXJObmlzeC1lc2NPUDBOLThIZFRJekZLQQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T15:41:26+00:00", "published_display": "11 May 2024 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for Innate Pharma (IPHA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFA0WTAzR2J3bDVCOTUyWlZNOFNZTG9TMi1NRXVPQUlRcWNYOTBGYnNDQkkteVN3RWZ5QzY0Q0lDMG9FOEkxcE1LQWtMNmdaZXRKNmRGZE5RcjY1NFU1UDN5cVk1c05IVklveVU2Ty1wNEZ6NVBidXUwRA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2023-03-14T02:28:08+00:00", "published_display": "14 Mar 2023 02:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma reports first half 2021 financial results and business update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQMmtzaG1WdnF4c0pCZ2cxell3WHNmUkt5Z0lrNmhvZXFIRDQ5MkVPNDJxYWl4SVlHaUx5NkxSakU3QXV3aHJTbktyS1JlMEFRT0oxSUZQWlg1UjVOMC1GamxlT0QzbUR4VXpDdmdjeW5EUEwxalREWmFyLUZXeEJvakxWWHgwcmVMREpka2xTTkJmX0ZWbFJSS21XSGxjQV9wUGVCSXRST1cwNmZ4VWhSa3ZVU0lSMVpKWG1vQXFSUkFqZmFXc0haNER3cXFMTnQxa2xMR2JQalpLeUNGbFVNUHdYelQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2021-09-15T07:00:00+00:00", "published_display": "15 Sep 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma reports full year 2019 financial results and business update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxQVzZ0dUs4eDhHNThrN3gxSXF0aE15LUxuak9fNUtTUC03SEdPbDcwOElZV0ZqX2hVTk9faHNxdjlfR0ZVNGtWRXJqVk5Gc2h4a25PVkFBSWdpVk1oSEp1bk1pWE5rN3BpOU92bjc2WVRBNG4zUXpXTzBUT0hibkhPaDhiakZTMjBsejRKZ0tHRnE2QU5pY2s0UkZHUDkwMDJoeklTYkllT3lwQWw3ZmxaOFMyR2NDNG1sYWh4Z25yUVdzMmxSSS1FTk14RUhsaktSTUh5VlFwVFRoWFFQSEFZ?oc=5", "source_name": "GlobeNewswire", "published_at": "2020-03-10T07:00:00+00:00", "published_display": "10 Mar 2020 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (IPHA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1NdWhfblZkZXJxbVVJTGE4SUdSNXhhOUdqY3dYSzBQcnJBOUpBYzlJZnNReDBELWxJbVpfSDJ0b3BzVmoxZEdhOXNyUWo2NldDY3B4NTJ0V0hNZw?oc=5", "source_name": "MarketBeat", "published_at": "2019-11-01T17:50:51+00:00", "published_display": "01 Nov 2019 17:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IPHA Stock Price and Chart \u2014 NASDAQ:IPHA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1BVTBfTDRPMkpOTnNOYmZjanY2Rnk1ZU8ycUQ4MGduYXF5cHEtNnRjYmUwY1hRcS1zbWRMdFJUVlpFclZzNUtFZEtMRE80MUdxbmRHT3EwSTNnZWV3?oc=5", "source_name": "TradingView", "published_at": "2019-10-19T11:50:07+00:00", "published_display": "19 Oct 2019 11:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Innate Pharma (IPHA) Edges Higher Near Key Support; Resistance at $1.88 in Focus - Breakaway Gap", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNSDQ5N0MzYUhoLUVzeE9pYWZmQmRlTlNLU2t5N2dPZ1RkY3ZSbU9UaEJQVDc2WE1DX2dnbzNXVi0tdEphS1Q3ME5nSnh3TERHR0ZHZ09USUxxamh4dlFOTjBVQzhCSDlpbm93alJnSW43emNzQ05IZ1cxc3VreEp5eXlfWGQ5QVBaWnFwaHlBdl9paHJpS3E2ZTJQOFNveE5ZM2dqOXFaX2JZaTYxSFRJUjllQno0T1d3bWZBMw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-13T00:30:04+00:00", "published_display": "13 Jul 2026 00:30", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (IPHA) Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical Investment Intensifies - Growth Acceleration Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPLTU4LVFBYnBMOVNNXzFuN05QNkhSX1p3b1FiQUp2V2RCLW1HNUdRUDdqTUtHb2VPcTlPWmtIcUR0TXhpTnJVVEY3OFFsQ29MV1hteFlNQU5ENXpsd195QzFudHlTeF9qRnk4VTBMU0JIZ25iLUZYNWgzTXFkVWNNcVN4dFh4WDJlT0tac1VPWWQxM1daZFZ5TlRINTI0LW9Bb1BQYm9EYkdrSEFrd043cER1enZuSk1WZE9rVTNiTlV0OEdja09DNlIwcG1tR3FzODJpaFFReEVJZEk?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-06T19:48:08+00:00", "published_display": "06 Jul 2026 19:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (IPHA) Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical Investment Intensifies - Guidance Revision Trend", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxQaVNIc1lzSWllRlpHeWQ4aDd3Tm5EN3JxOGE4NGFWcDNtT1l0TlhyWnJndk13ZmdiTjZlUmR0cC10ZDMyNktHb0plN1JHUGNGSVd1azhJWUtodmt3V2pqQjNyWExpX1RQUDZ4R3dnaGdVN3NhN2wwQjVHZXdwSG9qVy1hWTduSEhqcEwtT1FCQk82TnBEVFdPQnpzMG5BY294cWpWeEdsYWIyZVZfRThSMnJuSWFVdXpaZ2dhTFRYYlctRFlrNTZoalNRdVZtZnNrbVZ4OEhCekI?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-06T19:40:24+00:00", "published_display": "06 Jul 2026 19:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma(IPHA) Stock Options Chain | Quotes & News", "summary": "This article provides the stock options chain, quotes, and news for Innate Pharma (IPHA). It serves as a resource for investors interested in the company's financial performance and market derivatives. The content helps users access relevant financial data and recent updates for ", "url": "https://www.moomoo.com/stock/IPHA-US/options-chain?chain_id=Name1K9-3FXPhg.1kvnlg0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fstock%2F300300-SZ%22%7D", "source_name": "Moomoo", "published_at": "2026-07-06T20:10:53", "published_display": "06 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 2026 Innate Pharma SA Corporate Sales Call Transcript", "summary": "This document is a transcript of Innate Pharma SA's Q1 2026 Corporate Sales Call, which took place on May 13, 2026, at 11:30 AM GMT. The call covered the company's business and financial results for the first quarter of 2026, with a question-and-answer session following the initi", "url": "https://www.gurufocus.com/stock/CHIX:IPHP/transcripts/8856229", "source_name": "GuruFocus", "published_at": "2026-07-02T14:40:34", "published_display": "02 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Innate Pharma SA Class A \u2013 EURONEXT:IPH", "summary": "This article provides the \"Price to earnings forward\" value for Innate Pharma SA Class A (EURONEXT:IPH) as presented on TradingView. The page indicates the market is closed with no trades. It also highlights the data sources and copyright information for the financial data presen", "url": "https://www.tradingview.com/symbols/EURONEXT-IPH/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T16:40:49", "published_display": "30 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Innate Pharma SA Class A \u2013 EURONEXT:IPH", "summary": "This article displays the enterprise value to EBITDA forward for Innate Pharma SA Class A (EURONEXT:IPH) on TradingView. It appears to be a financial data snippet rather than a full analytical report, showing the period, value, and change percentages for this metric. The main con", "url": "https://www.tradingview.com/symbols/EURONEXT-IPH/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T15:39:53", "published_display": "28 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Innate Pharma SA Class A \u2013 EURONEXT:IPH", "summary": "This page provides financial information for Innate Pharma SA Class A (EURONEXT:IPH), specifically focusing on its Price to Sales Forward metric. The content highlights that the market was closed with no trades at the time of viewing, indicating a static financial snapshot for th", "url": "https://www.tradingview.com/symbols/EURONEXT-IPH/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:10:33", "published_display": "26 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Innate Pharma SA Class A \u2013 EURONEXT:IPH", "summary": "The page displays information regarding the \"Price to book forward\" for Innate Pharma SA Class A (EURONEXT:IPH). The article is primarily a data placeholder from TradingView, indicating financial metrics for the company.", "url": "https://www.tradingview.com/symbols/EURONEXT-IPH/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:11:43", "published_display": "25 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amendment: Innate Pharma (NASDAQ: IPHA) shows Novo Nordisk 0% ownership", "summary": "Novo Nordisk A/S filed an amended Schedule 13G/A, reporting zero beneficial ownership of Innate Pharma's ordinary shares, representing 0.00% of the company. The filing, signed by CFO Karsten Munk Knudsen on June 22, 2026, is an administrative amendment indicating no current discl", "url": "https://www.stocktitan.net/sec-filings/IPHA/schedule-13g-a-innate-pharma-sa-amended-passive-investment-disclosure-b870c4209af9.html", "source_name": "Stock Titan", "published_at": "2026-06-22T12:09:57", "published_display": "22 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13G Innate Pharma SA For: 22 June By Investing.com", "summary": "This article from Investing.com announces the filing of Form 13G for Innate Pharma SA (IPH) on June 22. It is a brief news item indicating a regulatory filing has occurred, primarily serving as an update for investors following the company. The content itself is very short and di", "url": "https://ng.investing.com/news/stock-market-news/form-13g-innate-pharma-sa-for-22-june-93CH-2567598", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T10:10:55", "published_display": "22 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma SA (IPHA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Innate Pharma SA (IPHA), focusing on its P/E, P/B, and Fair Value. The analysis indicates that relevant data for P/E, P/B, P/S, and P/CF have not yet been disclosed by the company. TradingKey provides this information as part of its ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ipha/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T16:40:10", "published_display": "18 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma SA (IPHA) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Innate Pharma SA (IPHA), detailing various metrics related to volatility, financial risk, and investment risk. It includes data on beta, VaR, maximum drawdown, daily returns, Sharpe Ratio, and turnover rates across different timeframes.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ipha/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:28", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma SA (IPHA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Innate Pharma SA (IPHA) has an average analyst rating of \"Buy\" based on 4 analysts, with a target price of USD 6.00, suggesting a significant upside. The article highlights that relevant earnings per share (EPS), revenue, net profit, and EBIT data have not yet been disclosed by t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ipha/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:27", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma SA (IPHA) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Innate Pharma SA's (IPHA) institutional confidence, including its current stock price, market capitalization, and a list of institutional shareholders. Key shareholders like AstraZeneca PLC and Lion Point Capital, L.P. are list", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ipha/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:27", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma SA (IPHA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Innate Pharma SA's (IPHA) dividend and stock split history. It states that the company has not distributed any dividends over the past five years and contains no record of historical stock splits. The page also displays current stock quotes an", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ipha/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T18:09:54", "published_display": "17 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma SA (IPHA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey focuses on Innate Pharma SA's (IPHA) revenue breakdown, noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It provides current stock information for IPHA, includ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ipha/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T18:09:54", "published_display": "17 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IPHA - Innate Pharma ADR Stock Price and Quote", "summary": "This page provides detailed financial information, stock performance data, and news updates for Innate Pharma ADR (IPHA). It includes key metrics such as market cap, income, sales, and various financial ratios, alongside a comprehensive list of analyst ratings and historical news", "url": "https://finviz.com/stock?t=IPHA", "source_name": "Finviz", "published_at": "2026-06-06T16:12:17", "published_display": "06 Jun 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (IPHA) Q1 2026 Earnings: Deep EPS Miss Weighs on Shares as Pipeline Progress Remains in Focus - Surprise Factor Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOT1EzeEZsbk91YmVtOHlkQ3g4YTI4UEJiSG5pRmVCcHM3Wlo2RUpPMG5VbjhLMkhBWXQxZXFNZml4TjAzWHd6UE9zNEl3YVduZ2xHWkx4Y3MyeHZrUm9BMFlMS0RtYXJuQXpGWVBVM2lxQVhtbGZGc2xzYWdIdHNxZjVGUHpWaXBZb3BEc0U0a0RVeFRQVEhlT0ZPSUY1cUFKSnltX3lzbnE4Ujd0NnhXbzhkTzVSdHlGcW4xS0tFdlhBTFd5T0poSzZDNjJ2Q3pzNlNsSVZpaWsxYkJtRG1J?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (Nasdaq: IPHA) outlines 2026 AGM quorum and key pipeline focus", "summary": "Innate Pharma (Nasdaq: IPHA) announced the voting results of its 2026 Annual General Meeting held on May 21, 2026, in Marseille. All resolutions were voted upon, with a total of 94 votes cast representing 34,921,313 voting rights and achieving a 37,136% quorum. The company also h", "url": "https://www.stocktitan.net/sec-filings/IPHA/6-k-innate-pharma-sa-current-report-foreign-issuer-f698fc38e19d.html", "source_name": "Stock Titan", "published_at": "2026-05-22T09:40:13", "published_display": "22 May 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outcome of Innate Pharma\u2019s 2026 Annual General Meeting", "summary": "Innate Pharma SA announced the voting results of its 2026 Annual General Meeting held on May 21, 2026, in Marseille. All proposed resolutions were approved by shareholders, with details available on the company's website. Innate Pharma is a clinical-stage biotechnology company fo", "url": "https://www.biospace.com/press-releases/outcome-of-innate-pharmas-2026-annual-general-meeting", "source_name": "BioSpace", "published_at": "2026-05-22T09:09:39", "published_display": "22 May 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholder turnout and votes at Innate Pharma\u2019s 2026 annual meeting", "summary": "Innate Pharma SA announced the voting results of its Annual General Meeting (AGM) held on May 21, 2026, in Marseille. All resolutions were passed, with a quorum of 37,136% representing 94 votes cast out of 34,872,293 shares. The company is a clinical-stage biotechnology firm focu", "url": "https://www.stocktitan.net/news/IPHA/outcome-of-innate-pharma-s-2026-annual-general-0itg9xbxnlrv.html", "source_name": "Stock Titan", "published_at": "2026-05-22T01:00:00", "published_display": "22 May 2026 01:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma to Court Investors at Jefferies Global Healthcare Conference 2026", "summary": "Innate Pharma SA announced that its executive team will hold one-on-one investor meetings at the Jefferies Global Healthcare Conference from June 2 to 4, 2026, in New York. The company aims to showcase its oncology pipeline, including assets like Nectin-4 ADC IPH4502, to U.S. inv", "url": "https://www.tipranks.com/news/company-announcements/innate-pharma-to-court-investors-at-jefferies-global-healthcare-conference-2026", "source_name": "TipRanks", "published_at": "2026-05-19T10:39:20", "published_display": "19 May 2026 10:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (Nasdaq: IPHA) to meet investors at Jefferies Global Healthcare Conference 2026", "summary": "Innate Pharma S.A. (Nasdaq: IPHA), a clinical-stage biotechnology company, announced its executive team will attend the Jefferies Global Healthcare Conference 2026 from June 2-4 in New York for one-on-one investor meetings. The company will showcase its pipeline of antibody-based", "url": "https://www.stocktitan.net/sec-filings/IPHA/6-k-innate-pharma-sa-current-report-foreign-issuer-b11c9bbd35e1.html", "source_name": "Stock Titan", "published_at": "2026-05-19T09:39:20", "published_display": "19 May 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma to participate in the Jefferies Global Healthcare Conference", "summary": "Innate Pharma SA, a clinical-stage biotechnology company focused on cancer immunotherapies, announced that its executive team will attend the Jefferies Global Healthcare Conference in New York from June 2\u20134, 2026. The team will participate in one-on-one investor meetings at the e", "url": "https://www.businesswire.com/news/home/20260518085378/en/Innate-Pharma-to-participate-in-the-Jefferies-Global-Healthcare-Conference", "source_name": "Business Wire", "published_at": "2026-05-19T07:40:16", "published_display": "19 May 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Innate Pharma Q1 2026 beats earnings expectations By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQdzJXV3dYM2RPQ3NkOTBSRFRfTy10OENPVDVFcEplVEJHb2ZLcEhKQ2h4U1ktekFTYmRiX1pkOVZjVmMzSnFNQW1EemlSMm1mYm1DUEZucmFtRUFZUmtQQzNFUWttVC1Lb1ZmSW96RERsQm5lREplc0dlOE5hakFOOHBHMHcxdTNsdzZ4Yk5BQ0xDbHVXcTcyT1VwbzF4a3A1eE92MkxtRXNJXzd3LTN5aWltajhZcXRSc1lPem9lZWxUUXIwWlg1MjNZak41d0ZS?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma S.A. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:IPHA) 2026-05-15", "summary": "This article announces that Innate Pharma S.A. has published its slide deck in conjunction with its 2026 Q1 earnings call. The content is provided by SA Transcripts, which focuses on developing and publishing earnings call transcripts.", "url": "https://seekingalpha.com/article/4905521-innate-pharma-s-a-2026-q1-results-earnings-call-presentation", "source_name": "Seeking Alpha", "published_at": "2026-05-16T00:09:51", "published_display": "16 May 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Innate Pharma(IPHA.US) With Buy Rating, Maintains Target Price $5", "summary": "H.C. Wainwright has reiterated its Buy rating for Innate Pharma (IPHA.US), maintaining a target price of $5. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance and potential.", "url": "https://www.moomoo.com/news/post/70005168/hc-wainwright-maintains-innate-pharma-iphaus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-05-15T02:40:36", "published_display": "15 May 2026 02:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma S.A. (NASDAQ:IPHA) Q1 2026 Earnings Call Transcript", "summary": "Innate Pharma S.A. held its Q1 2026 earnings call, exceeding EPS expectations. The company provided updates on its key pipeline assets: lacutamab, IPH4502, and partnered programs with AstraZeneca (monalizumab and IPH5201). Important upcoming milestones include the initiation of t", "url": "https://www.insidermonkey.com/blog/innate-pharma-s-a-nasdaqipha-q1-2026-earnings-call-transcript-1762053/", "source_name": "Insider Monkey", "published_at": "2026-05-14T12:38:54", "published_display": "14 May 2026 12:38", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IPHYF SEC Filings - Innate Pharma Marseille 10-K, 10-Q, 8-K Forms", "summary": "This article provides an overview of Innate Pharma S.A.'s (IPHYF) SEC filings, including 10-K, 10-Q, and 8-K forms, which detail the company's financial performance, oncology pipeline, and strategic collaborations. Recent filings highlight a 2025 net loss of \u20ac49.2 million with si", "url": "https://www.stocktitan.net/sec-filings/IPHYF/page-2.html", "source_name": "Stock Titan", "published_at": "2026-05-14T01:09:54", "published_display": "14 May 2026 01:09", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/f1f21d9b-235c-33d9-adbf-b83a4838b6df/innate-pharma-q1-earnings.html", "source_name": "MarketBeat", "published_at": "2026-05-13T16:07:22+00:00", "published_display": "13 May 2026 16:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (Nasdaq: IPHA) details Q1 2026 cash runway and trial plans", "summary": "Innate Pharma reported its Q1 2026 business update, highlighting plans for the TELLOMAK-3 confirmatory Phase 3 trial for lacutamab, contingent on non-dilutive financing. The company also provided updates on other pipeline assets, including IPH4502 and IPH5201, while noting its ca", "url": "https://www.stocktitan.net/sec-filings/IPHA/6-k-innate-pharma-sa-current-report-foreign-issuer-be09b6d5b541.html", "source_name": "Stock Titan", "published_at": "2026-05-13T12:09:12", "published_display": "13 May 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (IPHA) Reports Strong Revenue Growth in Q1 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQVmJwcGNEWVc4c3MyWHFqSGlhMFU1ODNqRVZKVDdIYXZveWVNbVY0dWI2dW1MRWlqalQxR2xuN2JEdjY3MEk2c1A5cldkQVdaUi13OVloNndwYWczcUlVLXdMR01GR2dzczd6ZjdmZFlwaVQ0eUx4LUNhYTdZd1h1Vm9HTGRScGtKd2F4ZXZnTjVJRXZGME5hTE00eUNZZGRsd0R0WFFjRmdXVzZ6emxn?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026", "summary": "Quantisnow published a press release detailing the number of shares and voting rights for Innate Pharma S.A. (IPHA) as of April 16, 2026. Quantisnow Plus members received an alert about this publication almost immediately after it was released. The platform provides real-time mar", "url": "https://www.quantisnow.com/insight/number-of-shares-and-voting-rights-of-innate-pharma-as-6546304", "source_name": "Quantisnow", "published_at": "2026-05-12T17:09:13", "published_display": "12 May 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma reports interim lung cancer trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPd2lIaDZzRHBoR2N2cW5MaE1yRzNsTVlyaWVsNDlrV2kyV2NrNVJVSTZpUjlBbHp0amZjazRRMWdhb19VVW1BU3ZUU2NNbUpTQzNWYXJJdXRWUnNoZG1SdmVBWWIycmx6YlIxbEI1MkhTRm5vT3RYU3N0T1lTZHV6OHFNWDFyRWZyLUFtUzhIam9uRGo3TDBHMjUzclRNU21yUDd0VEtQSGhSNDZvbFNQQWVR?oc=5", "source_name": "Investing.com", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma posts 2025 annual reports to French and US regulators", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNVi1Vakg5Q29XZE9kNnhLdWJaSUROeEhIWHRUcXBPUzd3Q1lmeGRKZjBoR090eUhCOUlwZnRCaE5kX0F2YzBPSjhQd3JESmd2WHN6eE5zM0QtcGtYdTF2M2Q2emZpS096MHh4bG80My01Sk0waXRKUlEtYUd1RWl3RVRubC12TEozRmt5Ql9zXzIxNWxJdTBoc1JOTm5pcFpNY1ZNMS1fSnE2S3ZVZXhJNHNIRDdpZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxNMENsbktULU5ZRFVEb1RocjI4VkZKX1Q4TzhvTHBpSklmTXpwcnlSWHhKQjhzNGpRcG5fT1ZscHJzU2xzbGg3Q015ZVoyN2lPMGVMRXI0dHdiT09FTDl2QlppZU1lNldpUVNMU1lqNHN5U2k2Rlo0cUxuOWJjTmR5WGluX2Iyb25qZnFFMVN1X0NfMWdGdTh0RFB4YmstVFpFVDlDVmVybVlZdW0yOEIwcnltSzhBdDRnS2pzVjBYNTE3eW5STzk2TlRzNzFqRTYzTFMyMWNB?oc=5", "source_name": "Investing.com", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (IPHA) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE5EV2Y3OVBiSG1IMzJtV1lMenY5bFh0ZlFXd2ZxSzlHTWJvWkk2T3VGR1JSZHVSelRDVnM3SFFRWkk3dDFfREpnY1hweW5GYXJObmlzeC1lc2NPUDBOLThIZFRJekZLQQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T15:41:26+00:00", "published_display": "11 May 2024 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for Innate Pharma (IPHA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFA0WTAzR2J3bDVCOTUyWlZNOFNZTG9TMi1NRXVPQUlRcWNYOTBGYnNDQkkteVN3RWZ5QzY0Q0lDMG9FOEkxcE1LQWtMNmdaZXRKNmRGZE5RcjY1NFU1UDN5cVk1c05IVklveVU2Ty1wNEZ6NVBidXUwRA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2023-03-14T02:28:08+00:00", "published_display": "14 Mar 2023 02:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma reports first half 2021 financial results and business update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQMmtzaG1WdnF4c0pCZ2cxell3WHNmUkt5Z0lrNmhvZXFIRDQ5MkVPNDJxYWl4SVlHaUx5NkxSakU3QXV3aHJTbktyS1JlMEFRT0oxSUZQWlg1UjVOMC1GamxlT0QzbUR4VXpDdmdjeW5EUEwxalREWmFyLUZXeEJvakxWWHgwcmVMREpka2xTTkJmX0ZWbFJSS21XSGxjQV9wUGVCSXRST1cwNmZ4VWhSa3ZVU0lSMVpKWG1vQXFSUkFqZmFXc0haNER3cXFMTnQxa2xMR2JQalpLeUNGbFVNUHdYelQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2021-09-15T07:00:00+00:00", "published_display": "15 Sep 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma reports full year 2019 financial results and business update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxQVzZ0dUs4eDhHNThrN3gxSXF0aE15LUxuak9fNUtTUC03SEdPbDcwOElZV0ZqX2hVTk9faHNxdjlfR0ZVNGtWRXJqVk5Gc2h4a25PVkFBSWdpVk1oSEp1bk1pWE5rN3BpOU92bjc2WVRBNG4zUXpXTzBUT0hibkhPaDhiakZTMjBsejRKZ0tHRnE2QU5pY2s0UkZHUDkwMDJoeklTYkllT3lwQWw3ZmxaOFMyR2NDNG1sYWh4Z25yUVdzMmxSSS1FTk14RUhsaktSTUh5VlFwVFRoWFFQSEFZ?oc=5", "source_name": "GlobeNewswire", "published_at": "2020-03-10T07:00:00+00:00", "published_display": "10 Mar 2020 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (IPHA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1NdWhfblZkZXJxbVVJTGE4SUdSNXhhOUdqY3dYSzBQcnJBOUpBYzlJZnNReDBELWxJbVpfSDJ0b3BzVmoxZEdhOXNyUWo2NldDY3B4NTJ0V0hNZw?oc=5", "source_name": "MarketBeat", "published_at": "2019-11-01T17:50:51+00:00", "published_display": "01 Nov 2019 17:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IPHA Stock Price and Chart \u2014 NASDAQ:IPHA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1BVTBfTDRPMkpOTnNOYmZjanY2Rnk1ZU8ycUQ4MGduYXF5cHEtNnRjYmUwY1hRcS1zbWRMdFJUVlpFclZzNUtFZEtMRE80MUdxbmRHT3EwSTNnZWV3?oc=5", "source_name": "TradingView", "published_at": "2019-10-19T11:50:07+00:00", "published_display": "19 Oct 2019 11:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 51, "sentiment_summary": {"positive": 7, "negative": 4, "neutral": 40, "score": 52, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 77, "events": [{"event": "earnings", "label": "Earnings", "weight": 13.55, "count": 26}, {"event": "general", "label": "Market update", "weight": 9.35, "count": 17}, {"event": "guidance", "label": "Guidance", "weight": 1.45, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 1.79, "latest_week": "2026-07-10", "one_week_move": -0.4, "four_week_move": 1.8, "twelve_week_move": 8.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.801815, "market_dynamics_buy_signal": false, "relative_strength": -15.2728, "fair_value_gap": -16.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 43.6121, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.4% over one week, +1.8% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 49, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "TradingKey", "count": 6}, {"label": "Market source", "count": 5}, {"label": "MarketBeat", "count": 3}, {"label": "dars.gov.et", "count": 2}, {"label": "Donan\u0131mHaber", "count": 2}, {"label": "Moomoo", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 26}, {"label": "Market update", "count": 17}, {"label": "Analyst action", "count": 2}, {"label": "Guidance", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Macro sensitivity", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-0.4% over one week, +1.8% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Innate Pharma (IPHA) Edges Higher Near Key Support; Resistance at $1.88 in Focus - Breakaway Gap"}], "updated_at": "2026-07-16T00:45:39.434924+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}